Drugs / Arachidonic Acid
Arachidonic Acid
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01576783 | Apr 2012 → Apr 2017 | — | Sarah Keim | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05191823 | Dec 2021 → Jun 2024 overdue | preterm premature rupture of the membranes | Sarah Keim | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arachidonic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05191823 ↗ |
| Known as | Arachidonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL15594 ↗ |
| Known as | Cis-5,8,11,14-eicosatetraenoic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL15594 ↗ |
| Modality | Small molecule | — CHEMBL15594 ↗ |